Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Tyra Biosciences (TYRA) reported a wider quarterly net loss as it advanced multiple clinical programs. For the three months ended September 30, 2025, the company posted a net loss of $29.9 million versus $24.0 million a year ago. Operating expenses rose to $32.9 million, driven by R&D of $25.5 million and G&A of $7.5 million, while interest and other income contributed $3.1 million.
Liquidity remains strong with cash, cash equivalents and marketable securities of $274.9 million as of September 30, 2025. Net cash used in operations was $71.5 million for the first nine months of 2025. Management states this cash position is expected to fund operations through at least 2027.
Development highlights include progress across FGFR programs: dabogratinib Phase 2 studies in pediatric achondroplasia (BEACH301) and NMIBC (SURF302) are underway, UTUC (SURF303) received FDA clearance to initiate Phase 2, and TYRA-430 began dosing in a global Phase 1. Shares outstanding were 53,318,198 as of September 30, 2025; 53,372,098 were outstanding as of October 31, 2025.
Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing lists the company’s common stock under the symbol TYRA on the Nasdaq Global Select Market.
Tyra Biosciences insider purchase under ESPP: The company's Chief Financial Officer, Alan Fuhrman, acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at a purchase price of $9.129 per share under the issuer's 2021 Employee Stock Purchase Plan. After the transaction, Mr. Fuhrman beneficially owned 14,788 shares. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Tyra Biosciences (TYRA) reported items from its Quarterly Report that describe capital structure, recent equity transactions, stock plan availability, cost drivers and development risks. The company had 53,233,494 shares issued and outstanding at June 30, 2025, compared with 50,754,262 issued and 50,749,945 outstanding at December 31, 2024. A 2022 Sales Agreement was terminated in May 2025 and no shares were sold under it; no shares had been sold under a 2025 Sales Agreement as of June 30, 2025. RA Capital exchanged 1,000,000 shares for pre-funded warrants exercisable at $0.001 per share; the Exchange closed October 22, 2024, and the warrants are classified in stockholders' equity. As of June 30, 2025, 5,189,786 shares were available for future grant under the 2021 Plan and 1,972,762 shares remained available for purchase under the ESPP, which offers a purchase price at 85% of the lower of two dates. The company disclosed increases in costs: $4.1 million and $9.6 million driven by clinical start-up and CMC activities, and increases of $2.4 million and $4.5 million in compensation and personnel expenses (including $1.0 million and $2.2 million higher stock-based compensation), partially offset by $0.2 million lower facilities costs. The filing lists numerous development, regulatory, operational and geopolitical risks that could affect timelines, costs and commercialization prospects.
Tyra Biosciences, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release, dated August 14, 2025, is included as Exhibit 99.1 to this report and is incorporated by reference. The company specifies that this earnings information, including the exhibit, is being furnished rather than filed, which limits how it is treated under certain liability provisions of U.S. securities laws.
Janus Henderson Group plc reported beneficial ownership of 2,856,290 shares of Tyra Biosciences common stock, equal to 5.4% of the class, in a Schedule 13G/A filing. The statement shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power, indicating the reported interest is held collectively by related entities. The filing identifies the reporting person type as IA, HC and lists indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios. A power of attorney authorizes named employees to prepare and file U.S. reporting forms on the group's behalf.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
